From PsychonautWiki
Jump to navigation Jump to search
Summary sheet: Meclofenoxate
Chemical Nomenclature
Common names Meclofenoxate, Centrophenoxine, Lucidril
Systematic name 2-Dimethylaminoethyl (4-chlorophenoxy)acetate
Class Membership
Psychoactive class Nootropic
Chemical class cholinergic
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.

Threshold 50 mg
Light 50 - 200 mg
Common 400 - 800 mg
Strong 800 - 1000 mg
Heavy 600 mg +

DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.


Meclofenoxate, also known as Centrophenoxine or Lucidril is a nootropic that acts as a precursor to choline. It is a an ester of Dimethylaminoethanol and para-chlorophenoxyacetic acid.

History and culture

Mecolofenoxate was developed in 1959 at the French National Scientific Research Center.[citation needed] Meclofenoxate has been tested as alzheimers treatment.[1] Additionally it has been shown to invrease the life span of mice by up to 29.5%.[2]


A portion of Meclofenoxate breaks down into DMAE and pCPA. DMAE is then converted to choline.

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects

Cognitive effects

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

Warning: contraindications for Meclofenoxate include depression, mania, epilepsy and convulsions.[3]

Meclofenoxate is non-addictive, is not known to cause harm, and has an extremely low toxicity relative to dose. Similar to many other nootropic substances, there are relatively few physical side effects associated with acute choline exposure. Various studies have shown that in reasonable doses in a particular context, it presents no negative cognitive, psychiatric or toxic physical consequences of any sort.

Regardless, it is strongly recommended that one is familiar with and uses harm reduction practices when using this substance.

Tolerance and addiction potential

Dangerous interactions

In vitro studies of meclofenoxate showed inhibition of total MAO, MAO A and MAO B in rat brains.[4] Meclofenoxate and MAOIs are a potentially dangerous combination. It is likely that MAOIs could increase the effects of meclofenoxate unpredictably. Taking this chemical while on prescription MAOIs is strongly discouraged.

Legal issues


This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • United States - Meclofenoxate is completely legal to purchase in the United States as a dietary supplement.

See also

External links


  1. Malík, Matěj; Tlustoš, Pavel (2022-08-17). "Nootropics as Cognitive Enhancers: Types, Dosage and Side Effects of Smart Drugs". Nutrients. 14 (16): 3367. doi:10.3390/nu14163367Freely accessible. ISSN 2072-6643. PMID 36014874. 
  2. Hochschild, R. (1973). "Effect of dimethylaminoethyl p-chlorophenoxyacetate on the life span of male swiss webster albino mice". Experimental Gerontology. 8 (4): 177–183. doi:10.1016/0531-5565(73)90024-7. 
  3. "Uses of Lucimax". Vinmec. 2012-11-30. Retrieved 2024-03-14. 
  4. SL, Stancheva; LG, Alova. "[Effect of centrophenoxine, piracetam and aniracetam on the monoamine oxidase activity in different brain structures of rats]". Farmakologiia i toksikologiia. Farmakol Toksikol. 51 (3). ISSN 0014-8318. PMID 3137089. Retrieved 2024-03-15.